Your browser doesn't support javascript.
loading
Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.
Masubuchi, Nami; Araki, Marito; Yang, Yinjie; Hayashi, Erina; Imai, Misa; Edahiro, Yoko; Hironaka, Yumi; Mizukami, Yoshihisa; Kihara, Yoshihiko; Takei, Hiraku; Nudejima, Mai; Koike, Masato; Ohsaka, Akimichi; Komatsu, Norio.
Afiliación
  • Masubuchi N; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Araki M; Research Institute for Disease of Old Age, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Yang Y; Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Hayashi E; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Imai M; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Edahiro Y; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Hironaka Y; Leading Center for the Development and Research of Cancer Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Mizukami Y; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Kihara Y; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Takei H; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Nudejima M; Center for Genomic and Regenerative Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Koike M; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Ohsaka A; Leading Center for the Development and Research of Cancer Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Komatsu N; Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Leukemia ; 34(2): 499-509, 2020 02.
Article en En | MEDLINE | ID: mdl-31462733
ABSTRACT
Studies have shown that mutant calreticulin (CALR) constitutively activates the thrombopoietin (TPO) receptor MPL and thus plays a causal role in the development of myeloproliferative neoplasms (MPNs). To further elucidate the molecular mechanism by which mutant CALR promotes MPN development, we studied the subcellular localization of mutant CALR and its importance for the oncogenic properties of mutant CALR. Here, mutant CALR accumulated in the Golgi apparatus, and its entrance into the secretion pathway and capacity to interact with N-glycan were required for its oncogenic capacity via the constitutive activation of MPL. Mutant CALR-dependent MPL activation was resistant to blockade of intracellular protein trafficking, suggesting that MPL is activated before reaching the cell surface. However, removal of MPL from the cell surface with trypsin shut down downstream activation, implying that the surface localization of MPL is required for mutant CALR-dependent activation. Furthermore, we found that mutant CALR and MPL interact on the cell surface. Based on these findings, we propose a model in which mutant CALR induces MPL activation on the cell surface to promote MPN development.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Calreticulina / Receptores de Trombopoyetina / Vías Secretoras / Mutación Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Calreticulina / Receptores de Trombopoyetina / Vías Secretoras / Mutación Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Japón